Clinical Trial Update: Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist [Phase 2]

View source ↗

Summary

Phase 2 trial update for CDB-2914 (a selective progesterone receptor antagonist) in treating uterine fibroids (leiomyoma) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyoma
• Uterine Fibroids

Drugs mentioned

• CDB-2914 (Ulipristal acetate)

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Leiomyoma | Phase 2 | Status: COMPLETED